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Background: Current standard radiotherapy for oropharynx cancer (OPC) is associated with high rates of
severe toxicities, shown to adversely impact patients’ quality of life. Given excellent outcomes of human
papilloma virus (HPV)-associated OPC and long-term survival of these typically young patients, treat-
ment de-intensification aimed at improving survivorship while maintaining excellent disease control is
now a central concern. The recent implementation of magnetic resonance image – guided radiotherapy
(MRgRT) systems allows for individual tumor response assessment during treatment and offers possibil-
ity of personalized dose-reduction. In this 2-stage Bayesian phase II study, we propose to examine weekly
radiotherapy dose-adaptation based on magnetic resonance imaging (MRI) evaluated tumor response.
Individual patient’s plan will be designed to optimize dose reduction to organs at risk and minimize
locoregional failure probability based on serial MRI during RT. Our primary aim is to assess the non-
inferiority of MRgRT dose adaptation for patients with low risk HPV-associated OPC compared to histor-
ical control, as measured by Bayesian posterior probability of locoregional control (LRC).
Methods: Patients with T1-2 N0-2b (as per AJCC 7th Edition) HPV-positive OPC, with lymph node <3 cm
and <10 pack-year smoking history planned for curative radiotherapy alone to a dose of 70 Gy in 33
20 H. Bahig et al. / Clinical and Translational Radiation Oncology 13 (2018) 19–23fractions will be eligible. All patients will undergo pre-treatment MRI and at least weekly intra-treatment
MRI. Patients undergoing MRgRT will have weekly adaptation of high dose planning target volume based
on gross tumor volume response. The stage 1 of this study will enroll 15 patients to MRgRT dose adap-
tation. If LRC at 6 months with MRgRT dose adaptation is found sufficiently safe as per the Bayesian
model, stage 2 of the protocol will expand enrollment to an additional 60 patients, randomized to either
MRgRT or standard IMRT.
Discussion: Multiple methods for safe treatment de-escalation in patients with HPV-positive OPC are cur-
rently being studied. By leveraging the ability of advanced MRI techniques to visualize tumor and soft
tissues through the course of treatment, this protocol proposes a workflow for safe personalized radiation
dose-reduction in good responders with radiosensitive tumors, while ensuring tumoricidal dose to more
radioresistant tumors. MRgRT dose adaptation could translate in reduced long term radiation toxicities
and improved survivorship while maintaining excellent LRC outcomes in favorable OPC.
Trial registration: ClinicalTrials.gov ID: NCT03224000; Registration date: 07/21/2017.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Background
1.1. Low risk HPV-Associated OPC
In the last decades, a change in the demographics of head and
neck cancers has been observed, with an increasing incidence of
human papillomavirus (HPV) – associated oropharyngeal cancers
(OPC) reaching 60% of all OPC in the United States [1]. HPV-
associated OPC is associated with markedly improved prognosis
compared to non-HPV-associated OPC [2,3]. The favorable progno-
sis, along with the long-term survival and markedly younger age
patients with HPV-positive disease, have supported that low-risk
HPV-associated OPC may be suitable for treatment de-
intensification [4]. Many treatment de-intensification strategies
are currently being assessed in the context of clinical trials; these
notably include use of minimally invasive surgery such as
trans-oral robotic surgery [5], targeted therapies [6], and various
radiation dose reduction strategies in the context of upfront radio-
therapy [7] or after induction chemotherapy [8,9].
1.2. MRgRT dose adaptation
The principle of adaptive radiotherapy planning relies on
adjusting the treatment plan based on observed changes over the
course of therapy. While tumor responsiveness to radiotherapy
in OPC has been shown to be associated with permanent tumor
control outcomes [10], intra-treatment tumor shrinkage is
observed as early as by fraction 11 [11] and complete response
at mid-treatment is observed in as high as 50% of patients with
HPV-associated OPC [12]. In a recent study, Lee et al. [7] reported
excellent disease control outcomes of 10 Gy dose de-escalation to
involved lymph nodes that presented early intra-treatment resolu-
tion of hypoxia on 18F-fluoromisonidazole - positron emission
tomography (PET).
The increasing use of magnetic resonance imaging (MRI) for
head and neck radiotherapy planning has the advantage of
improved soft-tissue visualization [13], allowing for more confi-
dent assessment of anatomical tumor changes during treatment,
at no ionizing radiation cost. The recent introduction of the MR-
Linac technology, consisting in the combination of a linear acceler-
ator and a 1.5 Tesla MRI, holds the promise to facilitate such adap-
tive MR-guided radiotherapy (MRgRT) workflows by mean of daily
on-line MRI during radiation treatment [14,15]. In this study, we
propose weekly RT dose-adaptation based on MRI-based tumor
response. This adaptive radiation protocol will target a highly
selected population of favorable risk HPV-associated OPC with a
small (<5–7%) probability of locoregional failure with photon
monotherapy. Our primary aim will be to assess the non-inferiority of MRgRT dose adaptation for patients with low risk
HPV-associated OPC compared to historical control, as measured
by Bayesian posterior probability of locoregional control (LRC).
By virtue of its assessment of clinical effectiveness and safety of
the use of weekly MRI for dose adaptation, this study is a stage
2a/2b study as per the R-IDEAL framework for systematic technol-
ogy assessment in radiotherapy [16] (Annex 1 – Supplementary
material).
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.ctro.2018.08.003.
2. Methods and design
2.1. Study design
This study uses a novel Phase II Bayesian two-stage adaptive
design. The stage 1 of this study will enroll 15 patients to the exper-
imental arm exclusively (MRgRT dose adaptation) to preliminarily
assess the efficacy and safety of MRgRT. Bayesian decision rules will
be used to make the go/no-go decision to move forward to stage 2, in
which 60 patients will be randomized (1:1 ratio) into the MRgRT
arm or the standard intensity modulated radiotherapy (IMRT) arm
for comparison of LRC. Fig. 1 presents the study scheme. This study
is approved by the MD Anderson Institutional Review Board and is
registered on clinicaltrials.gov (NCT03224000).
2.2. Primary objective
To assess non-inferiority of MRgRT dose adaptation and elective
volume de-escalation in low risk HPV-associated OPC treated with
radiotherapy alone.
 Primary endpoint:
o LRC at 6 months. LRC will be defined from time of treatment
completion to disease progression at primary site or regional
lymph nodes.
2.3. Secondary objectives
1. To compare rates of acute and late toxicities of MRgRT vs. stan-
dard IMRT.
2. To assess health – related quality of life outcomes in both treat-
ment groups.
3. To assess disease-related outcomes (2-year progression-free
survival, distant metastasis-free survival, and overall survival)
in both treatment groups.
4. To validate functional imaging kinetics as a correlate of early
treatment response.
Fig. 1. Scheme of the 2-stage trial design. ECOG = Eastern Cooperative Oncology Group; MRgRT = Magnetic-Resonance guided radiotherapy; IMRT = Intensity Modulated
Radiotherapy.
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 Biopsy proven diagnosis of squamous cell carcinoma of the
oropharynx (includes tonsil, soft palate, base of tongue, pharyn-
geal walls of oropharynx)
 Age 18 years
 Clinical stage T1-2, N0-1 (<3 cm), or small volume N2b (1–3 cm)
M0, per AJCC 7th edition
 Positive for HPV by p16 immunohistochemistry or HPV in-situ
hybridization
 Lifetime pack-year history of <10 years, and currently non-
smoking
 No retropharyngeal nor level IV lymphadenopathy
 No head and neck surgery of the primary tumor or lymph nodes
except for incisional or excisional biopsies
 Eastern Cooperative Oncology Group performance status 0–2
 Planned for single modality photon radiotherapy
 For females of child-bearing age, a negative pregnancy test
2.5. Conditions for patient ineligibility
 Previous radiation treatment for head and neck mucosal pri-
mary cancers within the past 5 years
 Pregnant or breast-feeding females
 Contraindications to MRI
2.6. Radiation therapy
Detailed description of target volumes and organs at risk (OAR)
dose constraints are presented in Annex 2 (Supplementary
material).
2.6.1. Dose specification
 MRgRT arm
Patients will receive an individualized prescription of up to
69.96 Gy in 33 fractions with radiotherapy administered once
daily, 5 days a week. Initial prescription will cover a high-risk clin-
ical region (CTV_6996) with 2.12 Gy/day. High-risk clinical region
will include the gross tumor volume (GTV) plus an additional
5 mm margin. All uninvolved upper-neck elective nodal volumes
outside of the CTV_6996 will be encompassed in an elective irradi-
ation volume deemed CTV_5016, and prescribed 1.52 Gy/day for a
total prescription of 50.16 Gy in 33 fractions. Standard IMRT arm
Patients will receive 69.96 Gy in 33 fractions to the high-risk
CTV_6996, with radiotherapy administered once daily, 5 days a
week. High-risk clinical region will include the GTV determined
on MRI plus an additional 5 mm margin. All uninvolved upper-
neck elective nodal volumes outside of the high-risk CTV will be
encompassed in a volume deemed CTV_5412, and prescribed
1.64 Gy/day for a total prescription of 54.12 Gy in 33 fractions.2.6.2. MRgRT arm: weekly adaptive workflow
Patients in the MRgRT arm will have pre-treatment and weekly
CT simulation and MR-simulation at an interval of 5 ± 2 fractions
serially on treatment. MRI imaging data will be acquired for all
patients in stage 1 of the trial using a non-hybrid MRI device
(MAGNETOM Aera 1.5 T MR scanner; Siemens Healthcare,
Erlangen, Germany). In stage 2, MRI imaging data will be acquired
using the integrated MR-Linac, which combines Philips 1.5 T MRI
(Marlin, Finland) with 7 MV photon beam Elekta Linear accelerator.
Anatomic T1-weighted and T2-weighted MRI sequences will be
acquired in the axial plane with diffusion weighting gradients in
three orthogonal directions using multiple b-values in the range
of 0–1500 s/mm2. The radiation plan adaptation will be done once
weekly and could be done online or offline. The diffusion weighted
images will be obtained and analyzed retrospectively to correlate
apparent diffusion coefficient (ADC) changes during treatment
with final treatment response.
With the aim to integrate weekly replanning as the default
workflow, weekly adaptation of the GTV (primary or nodal) will
be performed when a minimally measurable shrinkage of 2 mm
is observed. A new high-risk CTV_6996 will be generated to cover
the weekly MRI-based GTV plus a margin of 5 mm. Any region pre-
viously involved by the tumor will remain in the CTV_5016 to
receive the minimum daily dose of 1.52 Gy/day and ensure a min-
imum ‘‘floor” dose of 50.16 Gy.
On the standard IMRT arm, adaptation may be performed
exceptionally in cases where volumetric verification imaging is
concerning for inadequate coverage of the target volumes or dose
deviation to OAR.2.7. Radiation planning and IGRT
Patients will have planning CT and MRI positioned in a stable
supine position, using immobilization devices as previously
described [17]. All patients will be planned with IMRT or
22 H. Bahig et al. / Clinical and Translational Radiation Oncology 13 (2018) 19–23volumetric arc therapy. All treatment plans are to be normalized to
provide at least 95% volume coverage of the PTV with the pre-
scribed dose. No voxel within the PTV should receive more than
110% of the prescribed dose. Patients will have daily image guid-
ance using in-room volumetric imaging prior to daily treatment.
2.8. Patients’ evaluations
Pre-treatment, patients will be evaluated independently by a
head and neck surgeon, a medical oncologist and a radiation oncol-
ogist. Annex 3 (Supplementary material) summarizes evaluations
at different time points of the study.
2.9. Statistical considerations
A novel Bayesian two-stage adaptive design will be used for this
phase II trial (see Fig. 1). Stage 1 involve only the experimental arm
(MRgRT), and 15 patients will be enrolled to preliminarily assess
the efficacy and safety of the experimental MRgRT. If MRgRT
demonstrates promising, non-inferior LRC with a margin of 5%,
compared to the historical LRC rate of 96%, as well as a rate of
grade  3 toxicity at 6-months < 30%, we will move forward to
stage 2, in which 60 patients will be randomized (ratio 1:1) into
the MRgRT arm or the standard IMRT arm. In stage 2, an interim
analysis will be conducted to monitor the LRC and toxicity after
30 patients are randomized. Bayesian decision rules will be
used to make the go/no-go decision for each stage (Annex 4,
Supplementary material). The endpoint of LRC at 6 months was
selected to allow for rapid Bayesian decision, and is based on evi-
dence that the risk of locoregional recurrence after complete
response within 12 weeks of treatment in HPV-associated OPC is
associated with < 5% locoregional recurrence rate at 5 years [18].3. Discussion
In the context of the rampant incidence of HPV-associated OPC,
there is crucial need to improve toxicity profiles in this population
of often young, long-term survivors. The overall goal of treatment
de-intensification strategies is to maintain the current very good
disease control outcomes while reducing treatment-induced mor-
bidity. To this end, it is essential that any dose adaptation strategy
be associated with appropriate selection of good radiotherapy
responders without compromising the chances of cure of poor
responders. By leveraging the ability of advanced MRI techniques
to visualize tumor and soft tissue characteristics through the
course of treatment, it is possible to identify these subgroups of
good responders and offer personalized dose-reduction. The intro-
duction of the MR-Linac technology offers a unique opportunity to
facilitate such adaptive MRgRT workflows by mean of daily on-line
MRI during treatment [14]. The use of a common hybrid MRI
device in the stage 2 of this study will allow the development of
a high volume adaptive radiotherapy workflow using standardized
imaging across multiple institutions, facilitated by the use of an
integrated tool set. However, the results of our study could ulti-
mately be scaled to any MRI device in radiotherapy.
While the use of adaptive MRI-based radiotherapy has the
advantage of inherently selecting good responders, there remain
concerns regarding the minimal radiobiological dose required at
the edge of the shrinking GTV. In a recent study by Hamming-
Vrieze et al. [20] the behaviour of tissue surrounding the GTV edge
of locally advanced oropharyngeal tumors was assessed by placing
fiducal markers at the tumor surface. The authors reported a larger
GTV displacement on MRI compared to that assessed using fiducial
markers, suggesting that part of the GTV was likely dissolving
instead of shrinking and, raising concern of possible under-dosage of microscopic disease with adaptive field reduction follow-
ing GTV shrinkage assessed on MRI. In our study, this concern is
addressed on one part by maintaining a 5 mm margin around the
shrinking GTV for the high dose CTV, and on the other part by pre-
serving an unchanged elective volume throughout the treatment,
regardless of tumor response, to ensure a tumoricidal floor dose
in all areas previously involved by tumor.
Recent report from an in silico study by our group [19] evaluat-
ing the dosimetric advantage of the proposed MRgRT dose adapta-
tion approach showed a mean dose reduction to target volume of
11 Gy, and a significant dose reduction to swallowing musculature
and thyroid gland which translated into a reduction of normal tis-
sue complication probability of dysphagia grade 2, feeding tube
persistence at 6-month, and hypothyroidism at 1-year post-
treatment [19]. As a second step, our proposed clinical study will
provide essential information on the clinical feasibility, safety
and clinical toxicity reduction of MRgRT dose adaptation in well-
selected patients. We propose a conservative approach to this
MRgRT dose de-escalation model, whereby only patients with
highly favorable, low stage and low volume burden HPV-
associated OPC will be eligible to enroll in this study. Should the
study demonstrate positive results, transposition of this adaptive
model to more advanced HPV-associated OPC would be subject
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